Serelaxin inhibits LPS-induce expression of ECM-related protein
in CFs
We investigated the expression of collagen I and collagen III, Compared
with control, LPS induced significantly increased the mRNA and protein
levels of collagen I and collagen III, and was significantly reduced the
expression of collagen I and collagen III in CFs following treatment
with serelaxin(Fig. 6A and B). Then, we analyzed the effects of
serelaxin on the expression of MMP-2 and MMP-9 using qRT-PCR and western
blotting. The results of qRT-PCR showed that serelaxin strongly
upregulated LPS-induced the mRNA expression levels of MMP-2 and MMP-9 in
CFs (Fig. 6C and D). Besides, the production of MMP-2 and MMP-9
remarkable decrease in LPS-induced. In addition, GW9662, a PPAR-γ
inhibitor, reduced the inhibitory effect of serelaxin on collagen I and
collagen III production.
Inhibition of NF-κB Expression Is Involved in the Protective
Effects of serelaxin. To test the mechanism of serelaxin
anti-inflammatory effects, we detected the expression of IκBα and P65
NF-κB. In Figures 7A and B, results showed that LPS induced significant
increase of IκBα mRNA and protein expression in CFs. Compared with the
control group, the phosphorylation levels of NF-κB P65 increased
markedly with LPS treatment(Figures 7C and D). However, the increase
was strongly inhibited by serelaxin treatment. However, GW9662, a PPAR-γ
inhibitor, reduced the inhibitory effect of serelaxin on P65 NF-κB and
IκBα production.